使用米铂-碘油混悬液重复经动脉化疗栓塞治疗肝细胞癌的可行性和安全性
Feasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin-Lipiodol Suspension for Hepatocellular Carcinoma.
作者信息
Matsumoto Tomohiro, Ichikawa Hitoshi, Imai Jin, Hayashi Toshihiko, Tomita Kosuke, Mine Takahiko, Kojima Seiichiro, Watanabe Norihito, Hasebe Terumitsu
机构信息
Department of Radiology, Tokai University Hachioji Hospital, Tokai University School of Medicine, Hachioji, Japan.
Department of Gastroenterology, Tokai University Hachioji Hospital, Tokai University School of Medicine, Hachioji, Japan.
出版信息
Anticancer Res. 2017 Jun;37(6):3183-3187. doi: 10.21873/anticanres.11678.
AIM
To retrospectively evaluate the feasibility and safety of repeated transarterial chemoembolization (TACE) three or more times using miriplatin-lipiodol (M-LPD) suspension (repeated M-LPD TACE) for hepatocellular carcinoma (HCC).
PATIENTS AND METHODS
Sixteen patients who underwent repeated M-LPD TACE were examined. Total dose of miriplatin, lipiodol and porous gelatin sponge particles and adverse events of the first and last M-LPD TACE were evaluated.
RESULTS
The mean±standard deviation (SD) of the total number of M-LPD TACE per patient was 3.7±1.1. The mean±SD dose of total miriplatin, lipiodol and porous gelatin sponge particles per patient was 303±103 mg, 21±7.3 ml and 84±57 mg, respectively. There were no significant differences in any adverse events between the first and last M-LPD TACE.
CONCLUSION
Repeated M-LPD TACE for HCC is feasible and safe in selected patients.
目的
回顾性评估使用米铂-碘油（M-LPD）混悬液进行三次或更多次重复经动脉化疗栓塞术（TACE，即重复M-LPD TACE）治疗肝细胞癌（HCC）的可行性和安全性。
患者与方法
对16例行重复M-LPD TACE的患者进行检查。评估米铂、碘油和多孔明胶海绵颗粒的总剂量以及首次和末次M-LPD TACE的不良事件。
结果
每位患者M-LPD TACE的平均次数±标准差（SD）为3.7±1.1。每位患者米铂、碘油和多孔明胶海绵颗粒的平均总剂量±SD分别为303±103毫克、21±7.3毫升和84±57毫克。首次和末次M-LPD TACE之间的任何不良事件均无显著差异。
结论
对于部分患者，重复M-LPD TACE治疗HCC是可行且安全的。
Zotero 插件